Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71, 209–249.

PubMed  Google Scholar 

Sharma, R. (2022). Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050. International Journal of Clinical Oncology, 27, 665–675.

Article  PubMed  PubMed Central  Google Scholar 

Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics. CA: A Cancer Journal for Clinicians, 69(2019), 7–34.

PubMed  Google Scholar 

Berghmans, T., Durieux, V., Hendriks, L. E. L., & Dingemans, A. M. (2020). Immunotherapy: From advanced NSCLC to early stages, an evolving concept. Frontiers in Medicine (Lausanne), 7, 90.

Article  Google Scholar 

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017). Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell, 168, 707–723.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raza, A., Merhi, M., Relecom, A., Fernandes, Q., Inchakalody, V., Gul, A. R. Z., Uddin, S., Homsi, M. U. A., & Dermime, S. (2020). Evolving dynamic biomarkers for prediction of immune responses to checkpoint inhibitors in cancer. Advances in Precision Medicine Oncology. https://doi.org/10.5772/intechopen.96494

Pilla, L., & Maccalli, C. (2018). Immune profiling of cancer patients treated with immunotherapy: Advances and challenges. Biomedicines, 6, 76.

Article  PubMed  PubMed Central  Google Scholar 

Raza, A., Mohsen, R., Kanbour, A., Zar Gul, A. R., Philip, A., Vijayakumar, S., Hydrose, S., Prabhu, K. S., Al-Suwaidi, A. K., Inchakalody, V. P., Merhi, M., Abo El-Ella, D. M., Tauro, M. A., Akbar, S., Al-Bozom, I., Abualainin, W., Al-Abdulla, R., Sirriya, S. A., Hassnad, S., … Demime, S. (2023). Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression. Frontiers in Immunology, 14, 1157100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pathak, R., Pharaon, R. R., Mohanty, A., Villaflor, V. M., Salgia, R., & Massarelli, E. (2020). Acquired resistance to PD-1/PD-L1 blockade in lung cancer: Mechanisms and patterns of failure. Cancers (Basel), 12, 3851.

Article  CAS  PubMed  Google Scholar 

Ye, X., & Weinberg, R. A. (2015). Epithelial-mesenchymal plasticity: A central regulator of cancer progression. Trends in Cell Biology, 25, 675–686.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nieto, M. A. (2013). Epithelial plasticity: A common theme in embryonic and cancer cells. Science, 342, 1234850.

Article  PubMed  Google Scholar 

Shibue, T., & Weinberg, R. A. (2017). EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nature Reviews Clinical Oncology, 14, 611–629.

Article  PubMed  PubMed Central  Google Scholar 

Shi, Z. D., Pang, K., Wu, Z. X., Dong, Y., Hao, L., Qin, J. X., Wang, W., Chen, Z. S., & Han, C. H. (2023). Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies. Signal Transduction and Targeted Therapy, 8, 113.

Article  PubMed  PubMed Central  Google Scholar 

Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020). Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduction and Targeted Therapy, 5, 228.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bakir, B., Chiarella, A. M., Pitarresi, J. R., & Rustgi, A. K. (2020). EMT, MET, plasticity, and tumor metastasis. Trends in Cell Biology, 30, 764–776.

Article  PubMed  PubMed Central  Google Scholar 

Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., Nilsson, M. B., Gudikote, J., Tran, H., Cardnell, R. J., Bearss, D. J., Warner, S. L., Foulks, J. M., Kanner, S. B., Gandhi, V., … Heymach, J. V. (2013). An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical Cancer Research, 19, 279–290.

Article  CAS  PubMed  Google Scholar 

Chae, Y. K., Chang, S., Ko, T., Anker, J., Agte, S., Iams, W., Choi, W. M., Lee, K., & Cruz, M. (2018). Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). Scientific reports, 8, 2918.

Article  PubMed  PubMed Central  Google Scholar 

Jeong, H., Koh, J., Kim, S., Song, S. G., Lee, S. H., Jeon, Y., Lee, C. H., Keam, B., Lee, S. H., Chung, D. H., & Jeon, Y. K. (2024). Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer. British journal of cancer, 131, 23–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo, L., Lee, Y. T., Zhou, Y., & Huang, Y. (2022). Targeting epigenetic regulatory machinery to overcome cancer therapy resistance. Seminars in Cancer Biology, 83, 487–502.

Article  CAS  PubMed  Google Scholar 

Wang, L., Dong, X., Ren, Y., Luo, J., Liu, P., Su, D., & Yang, X. (2018). Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. Cell Death & Disease, 9, 129.

Article  Google Scholar 

Hass, R., von der Ohe, J., & Ungefroren, H. (2020). The intimate relationship among EMT, MET and TME: A T(ransdifferentiation) E(nhancing) M(ix) to be exploited for therapeutic purposes. Cancers (Basel), 12, 3674.

Article  CAS  PubMed  Google Scholar 

Yochum, Z. A., Cades, J., Wang, H., Chatterjee, S., Simons, B. W., O’Brien, J. P., Khetarpal, S. K., Lemtiri-Chlieh, G., Myers, K. V., Huang, E. H., Rudin, C. M., Tran, P. T., & Burns, T. F. (2019). Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene, 38, 656–670.

Article  CAS  PubMed  Google Scholar 

Casciello, F., Windloch, K., Gannon, F., & Lee, J. S. (2015). Functional role of G9a histone methyltransferase in cancer. Frontiers in Immunology, 6, 487.

Article  PubMed  PubMed Central  Google Scholar 

Huang, J., Dorsey, J., Chuikov, S., Zhang, X., Jenuwein, T., Reinberg, D., & Berger, S. L. (2010). G9a and Glp methylate lysine 373 in the tumor suppressor p53. Journal of Biological Chemistry, 285, 9636–9641.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu, Y., Zheng, Y., Dai, M., Wu, J., Yu, B., Zhang, H., Kong, W., Wu, H., & Yu, X. (2019). Snail2 induced E-cadherin suppression and metastasis in lung carcinoma facilitated by G9a and HDACs. Cell Adhesion & Migration, 13, 285–292.

Article  Google Scholar 

Xie, M., Zhang, L., He, C. S., Xu, F., Liu, J. L., Hu, Z. H., Zhao, L. P., & Tian, Y. (2012). Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. Journal of Cellular Biochemistry, 113, 1501–1513.

Article  CAS  PubMed  Google Scholar 

Zheng, X., Yu, C., & Xu, M. (2021). Linking Tumor Microenvironment to Plasticity of Cancer Stem Cells: Mechanisms and Application in Cancer Therapy. Frontiers in Oncology, 11, 678333.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shintani, Y., Fujiwara, A., Kimura, T., Kawamura, T., Funaki, S., Minami, M., & Okumura, M. (2016). IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling. Journal of Thoracic Oncology, 11, 1482–1492.

Article  PubMed  Google Scholar 

Fernando, R. I., Hamilton, D. H., Dominguez, C., David, J. M., McCampbell, K. K., & Palena, C. (2016). IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. Oncotarget, 7, 42031–42044.

Article  PubMed  PubMed Central  Google Scholar 

Lou, Y., Diao, L., Cuentas, E. R., Denning, W. L., Chen, L., Fan, Y. H., Byers, L. A., Wang, J., Papadimitrakopoulou, V. A., Behrens, C., Rodriguez, J. C., Hwu, P., Wistuba, J. V., II., & Heymach, D.L. Gibbons. (2016). Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clinical Cancer Research, 22, 3630–3642.

Article  CAS  PubMed  PubMed Central